Evidence map›Paper›PMID 34480019›Full record

ArticleBlood cancer journal2021

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.

Karthik Ramasamy, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A Tuchman, Jacob Laubach, Cristina Gasparetto, Asher Chanan-Khan and 8 more

Open access · goldAbstract readClinical Trial, Phase ILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 5 countries.

Karthik RamasamyDepartment of Haematology, Oxford University Hospital, NHS Trust, Oxford, United Kingdom. Karthik.ramasamy@ndcls.ox.ac.uk.ORCID 0000-0003-3385-3707
Ajay NookaWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0003-4165-6869
Hang QuachUniversity of Melbourne, St. Vincent's Hospital, Fitzroy, VIC, Australia.
Myo HtutCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Rakesh PopatUniversity College London Hospitals, NHS Foundation Trust, London, United Kingdom.
Michaela LiedtkeStanford University Cancer Center, Stanford, CA, USA.
Sascha A TuchmanDivision of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0003-2109-1573
Jacob LaubachDept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Newton, MA, USA.ORCID 0000-0001-7565-2052
Cristina GasparettoDepartment of Medicine, Duke Univ. Medical Center, Durham, NC, USA.
Asher Chanan-KhanDivision of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
Mark HertzbergDepartment of Clinical Haematology, Prince of Wales Hospital, Sydney, NSW, Australia.
Mark deMarioRoche Pharma Research and Early Development, New York, NY, USA.
Eveline NueeschRoche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Evelyne ChesneRoche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Izolda FranjkovicRoche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
Katharina LechnerRoche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
Martin KornackerRoche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.ORCID 0000-0002-3502-928X
Hearn Jay ChoTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Roche (Switzerland) · CHRoche Pharma AG (Germany) · DECity of Hope · USDuke Medical Center · USEmory University · USHarvard University · USLa Roche College · USMultiple Myeloma Research Foundation · USOxford University Hospitals NHS Trust · GBPrince of Wales Hospital · AUStanford University · USThe University of Melbourne · AUUniversity College London Hospitals NHS Foundation Trust · GBUniversity of North Carolina at Chapel Hill · USWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMaximum Tolerated DoseMiddle AgedMultiple MyelomaThiadiazinesTreatment OutcomeAntineoplastic AgentsRO6870810Thiadiazines

Identifiers

PMID34480019
PMCPMC8417099
OpenAlexW3196556572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.